Thomas Stankovich - Jul 22, 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Jul 22, 2021
Transactions value $
-$139,778
Form type
4
Date filed
9/17/2021, 06:51 PM
Previous filing
Jun 24, 2021
Next filing
Aug 24, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Award $0 +282K +840.1% $0.00 316K Jul 22, 2021 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Award $0 +90.4K +28.6% $0.00 406K Jul 22, 2021 Direct F2
transaction RSLS Common Stock, $0.001 par value per share Sale -$140K -48.4K -11.9% $2.89 358K Sep 10, 2021 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F2 These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F3 These shares were sold to cover taxes in connection with the vesting of restricted stock units.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.